Correction to: REMIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (polaBR), CART therapies, and lenalidomide/rituximab (R2) based on realworld data in patients with relapsed/refractory diffuse large Bcell lymphoma.
Ann Hematol
; 102(9): 2643-2644, 2023 Sep.
Article
em En
| MEDLINE
| ID: mdl-37432417
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article